FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2467356095> ?p ?o ?g. }

• W2467356095 abstract "The Cancer Genome Atlas analysis revealed that somatic EGFR, receptor tyrosine-protein kinase erbB-2 (ERBB2), Erb-B2 receptor tyrosine kinase 3 (ERBB3) and Erb-B2 receptor tyrosine kinase 4 (ERBB4) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit (PIK3CA) in 19% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers. Because ERBB family mutations can activate the PI3K/AKT pathway and likely have similar canonical signalling effects to PI3K pathway mutations, we investigated their combined impact on response to neoadjuvant HER2-targeted therapies. Baseline tumour biopsies were available from 74 patients with HER2-positive breast cancer who were enrolled in the phase II TCHL neoadjuvant study (ICORG 10-05) assessing TCH (docetaxel, carboplatin, trastuzumab) (n = 38) versus TCL (docetaxel, carboplatin, lapatinib) (n = 10) versus TCHL (docetaxel, carboplatin, trastuzumab, lapatinib) (n = 40), each for six cycles. Activating mutations in PIK3CA and ERBB family genes were identified using mass spectrometry-based genotyping. Phosphatase and tensin homolog (PTEN) expression was assessed by immunohistochemistry. PIK3CA and/or ERBB family mutations were detected in 23 (31.1%) tumour samples tested, whereas PTEN expression was low in 31.1% of cases tested. Mutation frequency was similar in each treatment arm (31.3% in TCH arm, 30% in TCL arm and 31.3% in TCHL arm) and was not influenced by oestrogen receptor (ER) status (27.6% in ER-negative patients, 33.3% in ER-positive patients) or progesterone receptor (PR) status (32.6% in PR-negative patients, 29% in PR-positive patients). There was no significant difference in pathological complete response (pCR) rates between 47 patients with wild-type (WT) tumours and 22 patients whose tumours carried mutations (in either PIK3CA or ERBB family genes) (42.5% vs. 54.5%; p = 0.439). Similarly, there was no significant difference in pCR rates between patients with PIK3CA/ERBB family mutated/PTEN-low (i.e., PI3K-activated) tumours and patients without PI3K activation (50% vs. 44%; p = 0.769). However, in the TCHL (but not the TCH) group, the pCR rate was higher for 9 patients with PIK3CA/ERBB family mutated tumours than for 20 patients with PIK3CA/ERBB family WT tumours (77.8% vs. 35%; p = 0.05). Our results indicate that patients who receive neoadjuvant TCHL and have PIK3CA/ERBB family mutated tumours may be more likely to have a pCR than patients with WT tumours. ClinicalTrials.gov, NCT01485926 . Registered on 2 December 2011." @default.
• W2467356095 created "2016-07-22" @default.
• W2467356095 creator A5000250638 @default.
• W2467356095 creator A5006854533 @default.
• W2467356095 creator A5009415100 @default.
• W2467356095 creator A5010597176 @default.
• W2467356095 creator A5011649305 @default.
• W2467356095 creator A5013110248 @default.
• W2467356095 creator A5015297540 @default.
• W2467356095 creator A5021160836 @default.
• W2467356095 creator A5022077073 @default.
• W2467356095 creator A5029203077 @default.
• W2467356095 creator A5032546540 @default.
• W2467356095 creator A5046559742 @default.
• W2467356095 creator A5047981365 @default.
• W2467356095 creator A5056120784 @default.
• W2467356095 creator A5061321901 @default.
• W2467356095 creator A5066488338 @default.
• W2467356095 creator A5066558926 @default.
• W2467356095 creator A5072021902 @default.
• W2467356095 creator A5076383603 @default.
• W2467356095 creator A5076556096 @default.
• W2467356095 creator A5086054339 @default.
• W2467356095 creator A5086491038 @default.
• W2467356095 creator A5088858231 @default.
• W2467356095 creator A5090856144 @default.
• W2467356095 date "2017-07-27" @default.
• W2467356095 modified "2023-10-08" @default.
• W2467356095 title "Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies" @default.
• W2467356095 cites W1969653304 @default.
• W2467356095 cites W1977267072 @default.
• W2467356095 cites W1983378923 @default.
• W2467356095 cites W1997579117 @default.
• W2467356095 cites W2014135632 @default.
• W2467356095 cites W2014564738 @default.
• W2467356095 cites W2018169163 @default.
• W2467356095 cites W2020372547 @default.
• W2467356095 cites W2020387003 @default.
• W2467356095 cites W2040935952 @default.
• W2467356095 cites W2043506695 @default.
• W2467356095 cites W2046376183 @default.
• W2467356095 cites W2055235037 @default.
• W2467356095 cites W2055614052 @default.
• W2467356095 cites W2056183265 @default.
• W2467356095 cites W2059411043 @default.
• W2467356095 cites W2086064725 @default.
• W2467356095 cites W2087861588 @default.
• W2467356095 cites W2101299592 @default.
• W2467356095 cites W2104258204 @default.
• W2467356095 cites W2106036365 @default.
• W2467356095 cites W2107831804 @default.
• W2467356095 cites W2109189228 @default.
• W2467356095 cites W2109439031 @default.
• W2467356095 cites W2109529198 @default.
• W2467356095 cites W2110444464 @default.
• W2467356095 cites W2111578514 @default.
• W2467356095 cites W2112499354 @default.
• W2467356095 cites W2114843025 @default.
• W2467356095 cites W2117241186 @default.
• W2467356095 cites W2118419063 @default.
• W2467356095 cites W2125239609 @default.
• W2467356095 cites W2133613600 @default.
• W2467356095 cites W2136527721 @default.
• W2467356095 cites W2139236349 @default.
• W2467356095 cites W2141393790 @default.
• W2467356095 cites W2149441684 @default.
• W2467356095 cites W2149908785 @default.
• W2467356095 cites W2154923670 @default.
• W2467356095 cites W2159192794 @default.
• W2467356095 cites W2159967578 @default.
• W2467356095 cites W2161422104 @default.
• W2467356095 cites W2175026167 @default.
• W2467356095 cites W2308342896 @default.
• W2467356095 cites W2352525452 @default.
• W2467356095 doi "https://doi.org/10.1186/s13058-017-0883-9" @default.
• W2467356095 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5530949" @default.
• W2467356095 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28750640" @default.
• W2467356095 hasPublicationYear "2017" @default.
• W2467356095 type Work @default.
• W2467356095 sameAs 2467356095 @default.
• W2467356095 citedByCount "29" @default.
• W2467356095 countsByYear W24673560952018 @default.
• W2467356095 countsByYear W24673560952019 @default.
• W2467356095 countsByYear W24673560952020 @default.
• W2467356095 countsByYear W24673560952021 @default.
• W2467356095 countsByYear W24673560952022 @default.
• W2467356095 countsByYear W24673560952023 @default.
• W2467356095 crossrefType "journal-article" @default.
• W2467356095 hasAuthorship W2467356095A5000250638 @default.
• W2467356095 hasAuthorship W2467356095A5006854533 @default.
• W2467356095 hasAuthorship W2467356095A5009415100 @default.
• W2467356095 hasAuthorship W2467356095A5010597176 @default.
• W2467356095 hasAuthorship W2467356095A5011649305 @default.
• W2467356095 hasAuthorship W2467356095A5013110248 @default.
• W2467356095 hasAuthorship W2467356095A5015297540 @default.
• W2467356095 hasAuthorship W2467356095A5021160836 @default.
• W2467356095 hasAuthorship W2467356095A5022077073 @default.
• W2467356095 hasAuthorship W2467356095A5029203077 @default.
• W2467356095 hasAuthorship W2467356095A5032546540 @default.
• W2467356095 hasAuthorship W2467356095A5046559742 @default.

• next